Table 2.

Some iatrogenic mitochondrial myopathies.

	Mitochondrial Target	Mitochondrial Derangement	Clinical Disorders	References
Nucleoside analogues	Mitochondrial polymerase	mtDNA synthesi inhibition	Hepatic steatosis, lactic acidosis, myophaty, neuropathy, nephrotoxicity	[33,34]
Gentamicin, chloramphenicol, tetracycline	mtDNA	mtDNA synthesi inhibition	Deafness, renal failure, myopathy	[35,36]
Metformin	Complex I	Inhibition of NADH-ubiquinone oxidoreductase	Lactic acidosis, myophathy	[35,37]
Fibrates (clofibrate, gemfibrozil, fenofribate, etc)	Complex I	Inhibition of NADH-ubiquinone oxidoreductase I	Myopathy and rhabdomyolysis	[30,38]
Thiazolidinediones (pioglitazone, troglitazone)	Complex I	Inhibition of NADH-ubiquinone oxidoreductase	Liver failure, rhabdomyolysisr	[30,39,40]
doxorubicin	mtDNA	Mutations inducer	Cardiomyopathy	[41,42]
Cisplatin	mtDNA	Mutations inducer	Cardiomyopathy	[34,35,36]
Corticosteroids	Complex I	Inhibition of NADH-ubiquinone oxidoreductase	Myophathy	[34,43]
Local anaesthetic (bupivicane, lidocaine)	ATP synthase	Inhibition of complex V and oxidative phosphorylation	Myophathy	[34,35,36]
Propofol	Coenzyme Q	Inhibition of electron transport at CoQ level	rhabdomyolysis, heart failure, hepatomegaly, asystole	[36,44]
Statins (simvastatin, cerivastatin, etc)	Coenzyme Q; complex I	Inhibition of electron transport at level of complex I and CoQ	myopathy, rhabdomyolysis	[34,45]
Beta-blockers (metoprolol, propranol)	Complex I	Inhibition of NADH-ubiquinone oxidoreductase	myophathy	[46,47]